

BAYER AKTIENGESELLSCHAFT

Form 6-K

May 10, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2007
Commission File Number: 001-16829
Bayer Aktiengesellschaft
Bayer Corporation*
(Translation of registrant's name into English)
Bayerwerk, Gebaeude W11
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany
(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b)(1): N/A

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b)(7): N/A

Indicate by check mark whether, by furnishing the information contained in this form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☐

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

* Bayer Corporation is also the name of a wholly-owned subsidiary of the registrant in the United States.

Table of Contents

Table of Contents**Bayer Group Key Data**

million	1st Quarter 2006	1st Quarter 2007	Change	Full Year 2006
Net sales	6,791	8,335	+ 22.7%	28,956
Change in sales				
Volume	+ 4%	+ 8%		+ 5%
Price	+ 1%	0%		0%
Currency	+ 5%	5%		0%
Portfolio	+ 1%	+ 20%		+ 12%
EBITDA¹	1,436	1,774	+ 23.5%	4,675
<i>Special items</i>	<i>(128)</i>	<i>(216)</i>		<i>(909)</i>
<i>EBITDA before special items</i>	<i>1,564</i>	<i>1,990</i>	<i>+ 27.2%</i>	<i>5,584</i>
EBITDA margin before special items	23.0%	23.9%		19.3%
EBIT²	1,049	1,175	+ 12.0%	2,762
<i>Special items</i>	<i>(128)</i>	<i>(200)</i>		<i>(717)</i>
<i>EBIT before special items</i>	<i>1,177</i>	<i>1,375</i>	<i>+ 16.8%</i>	<i>3,479</i>
EBIT margin before special items	17.3%	16.5%		12.0%
Non-operating result	(210)	(218)	3.8%	(782)
Net income	600	2,809		1,683
Earnings per share (³)	0.82	3.44		2.22
Core earnings per share (⁴)	1.01	1.26		3.24
Gross cash flow⁵	1,089	1,411	+ 29.6%	3,913
Net cash flow⁶	38	375		3,928
Cash outflows for capital expenditures	419	201	52.0%	1,876
Research and development expenses	414	625	+ 51.0%	2,297
Depreciation and amortization	387	599	+ 54.8%	1,913
Number of employees at end of period⁷	82,400	105,100		106,000
Personnel expenses	1,486	1,898	+ 27.7%	6,630

2006 figures restated

¹ ebitda = ebit plus
amortization of

intangible assets and depreciation of property, plant and equipment. ebitda, ebitda before special items and ebitda margin are not defined in the International Financial Reporting Standards and should therefore be regarded only as supplementary information. The company considers underlying ebitda to be a more suitable indicator of operating performance since it is not affected by depreciation, amortization, write-downs/write-backs or special items. The company also believes that this indicator gives readers a clearer picture of the results of operations and ensures greater comparability of data over time. The underlying ebitda margin is calculated by dividing underlying ebitda by sales.

- ² ebit as shown in the income statement
- ³ Earnings per share as defined in IAS 33 = net income divided by the average number of shares. For details see page 37.
- ⁴ Core earnings per share is not defined in the International Financial Reporting Standards and should therefore be regarded only as supplementary information. The

company believes that this indicator gives readers a clearer picture of the results of operations and ensures greater comparability of data over time. The calculation of core earnings per share is explained on page 30.

⁵ Gross cash flow = income after taxes from continuing operations plus income taxes, plus/minus non-operating result, minus income taxes paid, plus depreciation, amortization and write-downs, minus write-backs, plus/minus changes in pension provisions, minus gains/plus losses on retirements of noncurrent assets, plus non-cash effects of the remeasurement of acquired assets. The change in pension provisions includes the elimination of non-cash components of the operating result. It also contains benefit payments during the year. For details see page 21f.

⁶ Net cash flow = cash flow from operating activities according to IAS 7

⁷ Number of employees in full-time equivalents

Contents

Group Management Report as of March 31, 2007

<u>Overview of Sales, Earnings and Financial Position</u>	4
<u>Future Perspectives</u>	6
<u>Performance by Subgroup and Segment</u>	6
<u>Bayer HealthCare</u>	8
<u>Bayer CropScience</u>	14
<u>Bayer MaterialScience</u>	18
<u>Performance by Region</u>	20
<u>Liquidity and Capital Resources</u>	21
<u>Employees</u>	23
<u>Legal Risks</u>	24
<u>Subsequent Events</u>	27
<u>Calculation of ebit(da) Before Special Items</u>	28
<u>Investor Information</u>	29
Consolidated Financial Statements as of March 31, 2007	
<u>Bayer Group Statements of Income</u>	31
<u>Bayer Group Balance Sheets</u>	32
<u>Bayer Group Statements of Cash Flows</u>	33
<u>Bayer Group Statements of Recognized Income and Expense</u>	34
<u>Key Data by Segment and Region</u>	35
<u>Notes to the Interim Report as of March 31, 2007</u>	37
Financial Calendar, Masthead	40

Table of Contents

Interim Report as of March 31, 2007

Jump in HealthCare sales and earnings

Bayer: excellent start to 2007

All subgroups on course for growth sales up 22.7 percent to 8.3 billion

EBITDA before special items climbs 27.2 percent to 2.0 billion

EBIT before special items moves ahead 16.8 percent to 1.4 billion

Group net income improves from 0.6 billion to 2.8 billion

Net debt reduced by 4.8 billion

Overview of Sales, Earnings and Financial Position

Bayer got off to an excellent start in 2007, substantially improving on its strong performance in the prior-year quarter.

Sales rose by 22.7 percent to 8,335 million (Q1 2006: 6,791 million). Revenues for the first three months of 2007 include 1,410 million in sales of the acquired products of Schering, Berlin, Germany. When adjusted for the effects of exchange rate shifts and portfolio changes, sales rose by 7.5 percent, with HealthCare (+7.9 percent), CropScience (+5.9 percent) and MaterialScience (+9.4 percent) all contributing to the increase.

The Group's **ebitda** before special items advanced by 27.2 percent to 1,990 million (Q1 2006: 1,564 million). The figure for HealthCare jumped by 103.9 percent to 948 million (Q1 2006: 465 million), mainly in light of the Schering AG acquisition and a solid performance by Consumer Health. At CropScience there was a 6.0 percent improvement to 584 million (Q1 2006: 551 million), particularly as a result of higher volumes and improved cost structures. **ebitda** before special items of MaterialScience fell by 24.1 percent from the high level of the prior-year quarter, to 409 million (Q1 2006: 539 million), largely due to increased raw material costs.

Table of Contents

Interim Report as of March 31, 2007

ebit before special items advanced by 16.8 percent in the first quarter of 2007, to 1,375 million (Q1 2006: 1,177 million). Earnings were diminished by special charges of 200 million (Q1 2006: 128 million). The acquisition and integration of Schering, Berlin, Germany, led to special charges of 139 million. Special charges of 61 million were incurred for restructuring at CropScience, MaterialScience and Bayer Industry Services. After special items, ebit of the Bayer Group moved ahead by 12.0 percent to 1,175 million (Q1 2006: 1,049 million). After a non-operating result of minus 218 million (Q1 2006: minus 210 million), pre-tax income came in at 957 million (Q1 2006: 839 million). The non-operating result contained net interest expense of 156 million (Q1 2006: 143 million). Here it should be noted that interest charges for the same period of the previous year were boosted by one-time effects, while financing costs in the first quarter of 2007 rose due to acquisitions. After tax expense of 301 million (Q1 2006: 277 million), income after taxes from continuing operations rose to 656 million (Q1 2006: 562 million). Income after taxes from discontinued operations was 2.2 billion, including divestment gains of 2.1 billion for the Diagnostics business and 0.1 billion for H.C. Starck. After minority stockholders' interest, net income of the Bayer Group amounted to 2,809 million (Q1 2006: 600 million). Earnings per share came to 3.44 (Q1 2006: 0.82).

Gross cash flow improved by 29.6 percent from the prior-year quarter, to 1,411 million (Q1 2006: 1,089 million), due to the strong growth in business and the inclusion of Schering, Berlin, Germany. Net cash flow rose by 337 million to 375 million (Q1 2006: 38 million). The total net cash flow including discontinued operations was 413 million. Net debt declined by 4.8 billion to 12.8 billion in the first quarter of 2007, due particularly to the proceeds from the divestments of the Diagnostics business and H.C. Starck. Provisions for pensions and other post-employment benefits declined by 0.4 billion compared with December 31, 2006, to 6.2 billion, mainly because of higher capital market interest.

Table of Contents

Interim Report as of March 31, 2007

Future Perspectives

Economic outlook

For 2007 we continue to expect the global economy to grow at a rate that is considerably faster than the long-term average. In our opinion, the economic slowdown in the United States will only have a moderate effect on the global economy. Robust growth in Europe and also in the emerging economies of Asia and Latin America is expected to compensate for the weakness in the United States. Although we anticipate that the global economy will maintain its current momentum, risks could result from continuing imbalances in the world economy. It is also very difficult to predict the development of oil prices. We therefore expect a positive trend across the MaterialScience market sectors, although the extent of this trend will vary from region to region. The global crop protection market is expected to expand compared to the previous year. We do not expect a major change in the performance of the pharmaceuticals market compared to the prior year.

Bayer Group sales and earnings forecast

In light of the very successful start to 2007, we confirm our positive outlook for the year. At the present time we are not altering the guidance we issued in March. For the full year we therefore continue to target more than 10 percent growth in both Group sales and underlying ebitda, along with a slight increase in the underlying ebitda margin. We remain confident of the trend in our HealthCare business. For the year as a whole we intend to grow with or faster than the market in all divisions and improve the underlying ebitda margin toward 24 percent.

The market environment for our CropScience business in the first quarter was positive as expected. Provided market conditions do not significantly deteriorate, we continue to expect that we will grow slightly faster than the market and improve the underlying ebitda margin toward 22 percent.

Following the anticipated strong start to the year, MaterialScience plans to achieve further volume growth in 2007 and expects to sustain a good, value-creating earnings level. Underlying ebitda in the second quarter is expected to be roughly on par with the first quarter.

Performance by Subgroup and Segment

Changes in corporate structure

Our business activities are grouped into the HealthCare, CropScience and MaterialScience subgroups.

As of March 31, 2007, our interest in the voting capital of Bayer Schering Pharma AG, Berlin, Germany, amounted to 96.3 percent. The acquired business of Schering, Berlin, Germany, is included in the Pharmaceuticals segment of the HealthCare subgroup as of June 23, 2006. This business is not included in the figures for the first quarter of 2006.

Table of Contents**Interim Report as of March 31, 2007**

The names Bayer Schering Pharma or Schering as used in this report always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively. The reference to Bayer Schering Pharma AG or Schering AG also includes business conducted by affiliated entities in countries outside Germany. Bayer Schering Pharma AG and Schering-Plough Corporation, New Jersey, United States, are unaffiliated companies that have been totally independent of each other for many years.

The commentaries in this report relate exclusively to continuing operations, except where specific reference is made to discontinued operations or to a total value (total). The Diagnostics Division and H.C. Starck, both now divested, and the Wolff Walsrode activities, divestment of which is pending, are reported as discontinued operations. The prior-year data are restated accordingly.

Key Data by Subgroup and Segment

	Sales		EBIT before special items*		EBITDA before special items*		EBITDA margin before special items*	
million	1st Quarter 2006	1st Quarter 2007	1st Quarter 2006	1st Quarter 2007	1st Quarter 2006	1st Quarter 2007	1st Quarter 2006	1st Quarter 2007
HealthCare	2,203	3,610	385	624	465	948	21.1%	26.3%
Pharmaceuticals	1,148	2,495	207	420	246	711	21.4%	28.5%
Consumer Health	1,055	1,115	178	204	219	237	20.8%	21.3%
CropScience	1,771	1,786	408	447	551	584	31.1%	32.7%
Crop Protection	1,413	1,434	285	343	406	461	28.7%	32.1%
Environmental Science, BioScience	358	352	123	104	145	123	40.5%	34.9%
MaterialScience	2,486	2,608	423	291	539	409	21.7%	15.7%
Materials	710	739	132	38	170	80	23.9%	10.8%
Systems	1,776	1,869	291	253	369	329	20.8%	17.6%
Reconciliation	331	331	(39)	13	9	49	2.7%	14.8%
Continuing operations	6,791	8,335	1,177	1,375	1,564	1,990	23.0%	23.9%

2006 figures restated

* for definition see
Bayer Group
Key Data on
page 2, also
page 28.

Sales by Segment in Percent, 1st Quarter 2007 (Q1 2006 in parentheses)

Table of Contents

Interim Report as of March 31, 2007

Bayer HealthCare

Sales of the **Bayer HealthCare** subgroup rose in the first quarter by 63.9 percent, or 1,407 million, to 3,610 million. The acquired business of Schering, Berlin, Germany, contributed 1,410 million to this figure. Currency- and portfolio-adjusted sales improved by 7.9 percent, due particularly to the gratifying trend in our Consumer Health segment.

ebitda before special items for this subgroup climbed by 103.9 percent to 948 million (Q1 2006: 465 million). Underlying **ebit** advanced by 239 million to 624 million (Q1 2006: 385 million). The special items totaling minus 139 million in our HealthCare business resulted from charges connected with the integration of Schering, Berlin, Germany. **ebit** of Bayer HealthCare moved ahead by 106 million, or 28.0 percent, to 485 million.

Pharmaceuticals

Sales of our **Pharmaceuticals** segment rose by 1,347 in the first quarter of 2007, to a total of 2,495 million (Q1 2006: 1,148 million), with the acquired business of Schering, Berlin, Germany, accounting for 1,410 million. Adjusted for currency and portfolio changes, sales expanded by 4.6 percent. Sharply higher sales of Nexavar® and Levitra® more than offset the expected decline for Cipro®/Ciprobay®.

The figures for the first quarter of 2006 do not contain the business of Schering, Berlin, Germany, acquired in June 2006. The commentaries given below on business developments related to the acquired products include comparisons with data for the first quarter of 2006 that were prepared by Schering AG, Berlin, Germany, and do not form part of the Bayer Group financial statements. We refer to those figures as *pro forma*. The acquired Schering business posted dynamic currency- and portfolio-adjusted sales growth of more than 5 percent.

Sales of the Primary Care business unit in the first three months of 2007 dipped by 1.8 percent to 773 million, but rose by 1.5 percent on a currency- and portfolio-adjusted basis. On a currency-adjusted basis, business with Levitra® developed particularly well, expanding by 14.7 percent, while sales of Avalox®/Avelox® also improved slightly in the first quarter, advancing by 3.8 percent. Increasing competition from generic products led to a marked decline for Cipro®/Ciprobay®, with sales dropping by 15.0 percent when adjusted for shifts in currency parities.

In our Women's Healthcare business unit, we achieved sales of 627 million in the first quarter. The main growth drivers were the oral contraceptives of the Yasmin®/yaz®/ Yasminelle® product line, sales of which rose by 41.1 percent (*pro forma*) when adjusted for currency changes. This positive performance was due particularly to the launch of Yasminelle® in Europe and of yaz® in the United States and Latin America. In January, the u.s. Food and Drug Administration (fda) expanded the registration for yaz®, which can now be used in the United States to treat moderately severe acne in women. Currency-adjusted sales of our intra-uterine system Mirena® also advanced by a pleasing 25.0 percent (*pro forma*) thanks mainly to strong growth in the United States.

Table of Contents**Interim Report as of March 31, 2007**

Bayer HealthCare million	1st Quarter 2006	1st Quarter 2007	Change %
Net sales	2,203	3,610	+ 63.9
EBITDA¹	459	783	+ 70.6
<i>Special items</i>	<i>(6)</i>	<i>(165)</i>	
<i>EBITDA before special items²</i>	<i>465</i>	<i>948</i>	<i>+ 103.9</i>
EBITDA margin before special items	21.1%	26.3%	
EBIT¹	379	485	+ 28.0
<i>Special items</i>	<i>(6)</i>	<i>(139)</i>	
<i>EBIT before special items²</i>	<i>385</i>	<i>624</i>	<i>+ 62.1</i>
Gross cash flow¹	292	557	+ 90.8
Net cash flow¹	43	383	

2006 figures restated

¹ for definition see
Bayer Group
Key Data on
page 2

² for definition see
also page 28

Pharmaceuticals million	1st Quarter 2006	1st Quarter 2007	Change %
Sales	1,148	2,495	+ 117.3
Primary Care ¹	787	773	-1.8
Women's Healthcare		627	
Diagnostic Imaging (including Medrad)		307	
Specialized Therapeutics		303	
Hematology/Cardiology	327	268	-18.0
Oncology ²	34	159	
Dermatology (Intendis)		58	
EBITDA³	241	546	+ 126.6
<i>Special items</i>	<i>(5)</i>	<i>(165)</i>	
<i>EBITDA before special items⁴</i>	<i>246</i>	<i>711</i>	<i>+ 189.0</i>
EBITDA margin before special items	21.4%	28.5%	
EBIT³	202	281	+ 39.1
<i>Special items</i>	<i>(5)</i>	<i>(139)</i>	
<i>EBIT before special items⁴</i>	<i>207</i>	<i>420</i>	<i>+ 102.9</i>
Gross cash flow³	162	390	+ 140.7

Net cash flow³	(11)	279
----------------------------------	-------------	------------

2006 figures restated

¹ Schering
andrology
business not
included in Q1
2006

² Schering
oncology
business not
included in Q1
2006

³ for definition see
Bayer Group
Key Data on
page 2

⁴ for definition see
also page 28

Table of Contents

Interim Report as of March 31, 2007

Sales of the Diagnostic Imaging business unit came to 307 million. Currency-adjusted sales of Magnevist® rose by 11.8 percent (pro forma), while those of Ultravist® fell by 20.8 percent (pro forma) from the prior-year quarter. Having voluntarily withdrawn the 370 mgI/ml formulation of Ultravist® in the summer of 2006, we resumed sales of this product in numerous countries in the first quarter of 2007. We expect to quickly proceed with distribution of this product in the remaining countries as well.

Sales of the Specialized Therapeutics business unit amounted to 303 million. Currency-adjusted sales of our top product Betaferon®/Betaseron® to treat multiple sclerosis (ms) expanded by 9.9 percent (pro forma) in the first quarter. To safeguard our Betaseron® business, we signed an agreement with Novartis in March 2007 to acquire the biologics manufacturing facility in Emeryville, California, currently used to produce Betaseron®. The acquisition is subject to the approval of the antitrust authorities. According to the terms of the agreement, Bayer will make a one-time payment to Novartis of approximately us\$ 110 million for the production facility, including the Biologics License Application (bla). Bayer Schering Pharma will continue to pay Novartis royalties equivalent to those being paid currently on net sales of Betaseron® manufactured by Bayer at the Emeryville facilities until the original agreement with Novartis expires in October 2008. After this date, no more royalties will be due to Novartis on the sales of Betaseron®. Bayer Schering Pharma will also acquire the existing inventories. In return, Novartis will receive a license to establish its own brand based on interferon beta-1b starting in 2009. When it is approved by the health authorities, Bayer Schering Pharma will manufacture the product for Novartis from 2009 forward and receive in return a low double-digit percentage royalty from Novartis.

Sales of the Hematology/Cardiology business unit fell by 18.0 percent to 268 million, mainly due to termination of the plasma distribution agreements for Canada and Germany. Adjusted for currency and portfolio changes, business was up by 3.7 percent. Currency-adjusted sales of Kogenate® advanced by 3.2 percent in the first quarter. At the end of January 2007, the European Commission granted an additional registration authorizing the use of Kogenate® for continuous infusion in hemophilia a patients undergoing major surgery. Currency-adjusted sales of Trasylo® declined by 4.4 percent. Two separate observational studies reported on a possible correlation between the administration of Trasylo® (aprotinin), our product for use during open-heart surgery, and severe renal dysfunction and vasoconstriction (myocardial infarction and stroke). A follow-up study to one of them reported on a possible correlation between administration of this product and increased long-term mortality. Based on our study data and many years of experience with Trasylo®, Bayer believes that this product is a safe and effective medicine when used correctly. We are currently cooperating closely with the relevant regulatory authorities to resolve the questions that have arisen.

Table of Contents**Interim Report as of March 31, 2007**

				Currency- adjusted
Best-Selling Pharmaceutical Products	1st	1st	Change	change
million	Quarter	Quarter	%	%
	2006	2007		
Betaferon®/Betaseron®* (Specialized Therapeutics)		244		
Yasmin®/YAZ®/Yasminelle®* (Women's Healthcare)		240		
Kogenate® (Hematology/Cardiology)	204	201	-1.5	+ 3.2
Adalat® (Primary Care)	157	145	-7.6	-0.9
Avalox®/Avelox® (Primary Care)	130	128	-1.5	+ 3.8
Cipro®/Ciprobay® (Primary Care)	132	108	-18.2	-15.0
Levitra® (Primary Care)	78	84	+ 7.7	+ 14.7
Mirena®* (Women's Healthcare)		81		
Magnevist®* (Diagnostic Imaging)		80		
Glucobay® (Primary Care)	77	72	-6.5	-1.2
Total	778	1,383	+ 77.8	+ 87.1
Proportion of Pharmaceuticals sales	68%	55%		

Products ranked by Q1 2007 sales

* acquired Schering AG product

				Currency- adjusted
Best-Selling Schering Products (pro forma)	1st	1st	Change	change
million	Quarter	Quarter	%	%
	2006	2007		
Betaferon®/Betaseron® (Specialized Therapeutics)	232	244	+ 5.2	+ 9.9
Yasmin®/YAZ®/Yasminelle® (Women's Healthcare)	180	240	33.3	+ 41.1
Mirena® (Women's Healthcare)	68	81	19.1	+ 25.0
Magnevist® (Diagnostic Imaging)	76	80	+ 5.3	+ 11.8

Table of Contents

Interim Report as of March 31, 2007

Our Oncology business unit lifted sales by 125 million to 159 million. Included in this figure is 98 million in sales of the acquired oncology business of Schering AG, Berlin, Germany, which mainly comprises the key products Fludara® and Campath®. Currency- and portfolio-adjusted sales rose by 83.6 percent. Our new cancer drug, Nexavar®, first launched in December 2005, performed very well in the market, with sales of 47 million (Q1 2006: 20 million). Study results for Nexavar® in liver cancer are also very promising. The phase iii study involving patients with advanced hepatocellular carcinoma reached its primary endpoint. Overall survival was significantly extended in patients treated with Nexavar®. Furthermore, Bayer plans to expand the registration of Campath®, developed jointly by Bayer and Genzyme, to include first-line treatment of b-cell chronic lymphocytic leukemia (b-ctl). Genzyme submitted the required supplemental license application to the fda on March 19, 2007 and to the European Medicines Agency (emea) on April 4, 2007.

The Dermatology (Intendis) business unit had sales of 58 million. Currency-adjusted sales of the principal products Skinoren® and Advantan® rose by 16.5 percent and 1.8 percent (pro forma), respectively.

ebitda of the **Pharmaceuticals** segment before special items advanced to 711 million in the first quarter of 2007, from 246 million in the same period of last year. This sharp increase is mainly due to the earnings contribution from the acquired business of Schering, Berlin, Germany, and to improved cost structures, including synergies already realized. **ebit** before special items rose by 213 million, or 102.9 percent, to 420 million. The special charges of 139 million in the Pharmaceuticals segment resulted from expenses for the acquisition and integration of Schering. **ebit** moved ahead by 79 million, or 39.1 percent, to 281 million.

Consumer Health

All divisions contributed to the gratifying performance of our **Consumer Health** segment, where **sales** improved by 5.7 percent to 1,115 million (Q1 2006: 1,055 million). On a currency-adjusted basis, business expanded by a substantial 11.4 percent.

Sales in the Consumer Care Division rose by 2.6 percent to 659 million (Q1 2006: 642 million), or by 8.1 percent on a currency-adjusted basis. Among our top products, Aleve® performed particularly well, with sales up 40.9 percent when adjusted for changes in currency parities, thanks mainly to the launch of Aleve® Liquid Gels in the United States.

There was a significant increase in sales of the Diabetes Care Division, where business improved by 17.1 percent to 226 million (Q1 2006: 193 million), due primarily to a strong performance by our blood glucose monitoring systems Ascensia® Contour® and Ascensia® Breeze®, which replace the older Elite® systems in the Ascensia® product family. Currency-adjusted sales of the division improved by an even more gratifying 23.0 percent.

Sales of the Animal Health Division rose by 4.5 percent to 230 million (Q1 2006: 220 million), or by 11.2 percent when adjusted for currency changes. The increase was primarily due to the encouraging performance of our Advantage® product line, especially in North America, sales of which rose 35.5 percent on a currency-adjusted basis.

Table of Contents**Interim Report as of March 31, 2007**

ebitda of the **Consumer Health** segment before special items grew by 18 million, or 8.2 percent, in the first quarter of 2007, to 237 million. Higher earnings resulting from the growth in sales more than offset an increase in marketing expenses to support the new product launches planned for 2007. ebit before special items advanced by 14.6 percent to 204 million (Q1 2006: 178 million). After special items, ebit improved by 15.3 percent to 204 million (Q1 2006: 177 million).

Consumer Health million	1st Quarter 2006	1st Quarter 2007	Change %
Net sales	1,055	1,115	+ 5.7
Consumer Care	642	659	+ 2.6
Diabetes Care	193	226	+ 17.1
Animal Health	220	230	+ 4.5
EBITDA*	218	237	+ 8.7
<i>Special items</i>	<i>(1)</i>	<i>0</i>	
<i>EBITDA before special items</i>	<i>219</i>	<i>237</i>	<i>+ 8.2</i>
EBITDA margin before special items	20.8%	21.3%	
EBIT*	177	204	+ 15.3
<i>Special items</i>	<i>(1)</i>	<i>0</i>	
<i>EBIT before special items</i>	<i>178</i>	<i>204</i>	<i>+ 14.6</i>
Gross cash flow*	130	167	+ 28.5
Net cash flow*	54	104	+ 92.6

2006 figures restated

* for definition see Bayer Group Key Data on page 2

Best-Selling Consumer Health Products million	1st Quarter 2006	1st Quarter 2007	Change %	Change currency- adjusted %
Ascensia® product line (Diabetes Care)	190	223	+ 17.4	+ 23.8
Aspirin®* (Consumer Care)	116	113	-2.6	+ 2.3
Advantage® product line (Animal Health)	59	75	+ 27.1	+ 35.5
Aleve®/naproxen (Consumer Care)	53	69	+ 30.2	+ 40.9
Canesten® (Consumer Care)	41	43	+ 4.9	+ 7.3
Baytril® (Animal Health)	40	40	0.0	+ 2.8
Bepanthen®/Bepanthol® (Consumer Care)	35	36	+ 2.9	+ 5.1
Supradyn® (Consumer Care)	35	33	-5.7	-3.2
One-A-Day® (Consumer Care)	30	31	+ 3.3	+ 12.1
Rennie® (Consumer Care)	26	27	+ 3.8	+ 5.4
Total	625	690	+ 10.4	+ 16.1
Proportion of Consumer Health sales	59%	62%		

* Total Aspirin®
sales =
167 million (Q1
2006:
164 million),
including
Aspirin® Cardio,
which is
reflected in sales
of the
Pharmaceuticals
segment

Table of Contents

Interim Report as of March 31, 2007

Bayer CropScience

Sales of our **CropScience** subgroup, at 1,786 million, showed a slight year-on-year increase (Q1 2006: 1,771 million). Adjusted for currency and portfolio changes, business expanded by a gratifying 5.9 percent.

ebitda before special items advanced by 33 million, or 6.0 percent, to 584 million. The combined effect of higher volumes and cost savings more than offset the pressure on margins from adverse shifts in currency parities. **ebit** before special items improved by 39 million, or 9.6 percent, to 447 million. Earnings were held back by special charges related to the restructuring project initiated in 2006. First-quarter ebit was steady at 408 million.

Crop Protection

First-quarter sales in the Crop Protection segment grew to 1,434 million (Q1 2006: 1,413 million). When adjusted for currency and portfolio changes, sales moved ahead 6.5 percent. The early start to the season in Europe, the increased cultivation of plants for the production of biofuels and internationally high prices for crop commodities led to growth in business, particularly in the Seed Treatment, Herbicides and Fungicides business units.

Sales of the Insecticides business unit fell by 37 million to 311 million. When adjusted for currency and portfolio changes, sales decreased by 4.2 percent. The decline should be viewed in light of the impact on our North American business of factors including a shift from soil- and foliar-applied insecticides to seed treatment products in the first quarter of this year. Sales in Europe increased, thanks mainly to a strong performance by our new insecticide Biscaya®.

Sales of the Fungicides business unit grew by 1.6 percent in the first quarter of 2007, to 384 million. On a currency-adjusted basis, the increase amounted to 4.2 percent. Buoyed by the trend in Europe, sales of our new cereal fungicides Proline® and Fandango®, in particular, made good gains. Business with our Flint® line of fungicide products benefited from a recovery in the Latin American market. The downward sales trend for our Folicur® product line was largely the result of a drop in business in the United States. Sales were hampered by the fact that our customers had built up substantial precautionary inventories in 2005/2006 for the prevention of Asian rust in soybeans. Another factor was the planned switch to the active ingredient prothioconazole, which received marketing authorization in the United States at the end of the first quarter of 2007.

Sales of the Herbicides business unit advanced by 3.3 percent to 568 million, with currency-adjusted growth amounting to 7.2 percent. The main reason for the improvement was the strong performance of our young cereal herbicides Atlantis®, Hussar® and Sekator®, particularly in Europe.

Table of Contents**Interim Report as of March 31, 2007**

Bayer CropScience million	1st Quarter 2006	1st Quarter 2007	Change %
Net sales	1,771	1,786	+ 0.8
EBITDA*	551	548	0.5
<i>Special items</i>	<i>0</i>	<i>(36)</i>	
<i>EBITDA before special items</i>	<i>551</i>	<i>584</i>	<i>+ 6.0</i>
EBITDA margin before special items	31.1%	32.7%	
EBIT*	408	408	0.0
<i>Special items</i>	<i>0</i>	<i>(39)</i>	
<i>EBIT before special items</i>	<i>408</i>	<i>447</i>	<i>+ 9.6</i>
Gross cash flow*	387	369	4.7
Net cash flow*	(350)	(238)	+ 32.0

* for definition see Bayer Group Key Data on page 2

Best-Selling Bayer CropScience Products* million	1st Quarter 2006	1st Quarter 2007	Change %	Currency- adjusted change %
Confidor®/Gaucho®/Admire®/Merit® (Insecticides/Seed Treatment/Environmental Science)	165	163	1.2	+ 3.1
Folicur®/Raxil® (Fungicides/Seed Treatment)	95	77	18.9	16.1
Atlantis® (Herbicides)	49	76	+ 55.1	+ 57.1
Proline® (Fungicides)	58	72	+ 24.1	+ 24.7
Basta®/Liberty® (Herbicides)	72	72	0.0	+ 8.0
Puma® (Herbicides)	68	69	+ 1.5	+ 7.5
Flint®/Stratego®/Sphere® (Fungicides)	49	60	+ 22.4	+ 29.1
Poncho® (Seed Treatment)	31	59	+ 90.3	+ 106.1
Hussar® (Herbicides)	32	47	+ 46.9	+ 44.6
Betanal® (Herbicides)	45	45	0.0	+ 2.2
Total	664	740	+ 11.4	+ 15.8
Proportion of Bayer CropScience sales	37%	41%		

* Figures are based on active ingredient class. For the sake of clarity, only the principal brands and business units are listed.

Crop Protection million	1st Quarter 2006	1st Quarter 2007	Change %
-----------------------------------	---------------------------------	---------------------------------	---------------------

Net sales	1,413	1,434	+ 1.5
Insecticides	348	311	10.6
Fungicides	378	384	+ 1.6
Herbicides	550	568	+ 3.3
Seed Treatment	137	171	+ 24.8
EBITDA*	406	425	+ 4.7
<i>Special items</i>	<i>0</i>	<i>(36)</i>	
<i>EBITDA before special items</i>	<i>406</i>	<i>461</i>	<i>+ 13.5</i>
EBITDA margin before special items	28.7%	32.1%	
EBIT*	285	304	+ 6.7
<i>Special items</i>	<i>0</i>	<i>(39)</i>	
<i>EBIT before special items</i>	<i>285</i>	<i>343</i>	<i>+ 20.4</i>
Gross cash flow*	285	282	1.1
Net cash flow*	(289)	(113)	+ 60.9

* for definition see Bayer Group Key Data on page 2

Table of Contents

Interim Report as of March 31, 2007

Sales of the Seed Treatment business unit advanced by a substantial 34 million, or 24.8 percent, to 171 million. The currency-adjusted increase was 31.1 percent. Our new insecticidal seed treatment Poncho®, in particular, performed very well in the market in light of an early start to the season in Europe and especially because of the planned increase in corn acreages in the United States to meet heightened demand for biofuels.

First-quarter **ebitda** before special items of our Crop Protection segment climbed by 13.5 percent year on year to 461 million, the positive overall sales trend and the savings achieved through our cost structure and efficiency improvement programs offsetting the currency-related squeeze on margins. **ebit** before special items in the first quarter came in at 343 million (Q1 2006: 285 million). After special items, ebit amounted to 304 million (Q1 2006: 285 million).

Environmental Science, BioScience

Sales of the Environmental Science, BioScience segment edged down 1.7 percent to 352 million, but rose by 3.7 percent on a currency-adjusted basis.

The Environmental Science unit recorded sales of 188 million, which was 2.6 percent below the prior-year figure. Currency-adjusted sales moved ahead 2.4 percent thanks to good business with home and garden products for consumers.

Sales of the BioScience unit held steady year on year at 164 million, though on a currency-adjusted basis they increased by 5.3 percent. The improvement was due particularly to the good development of our vegetable seed business.

ebitda before special items of the Environmental Science, BioScience segment fell by 22 million year on year to 123 million (Q1 2006: 145 million), due primarily to negative currency effects and increased research and development spending at BioScience. **ebit** fell by 19 million to 104 million (Q1 2006: 123 million).

Table of Contents

Interim Report as of March 31, 2007

Environmental Science, BioScience million	1st Quarter 2006	1st Quarter 2007	Change %
Net sales	358	352	1.7
Environmental Science	193	188	2.6
BioScience	165	164	0.6
EBITDA*	145	123	15.2
<i>Special items</i>	<i>0</i>	<i>0</i>	
<i>EBITDA before special items</i>	<i>145</i>	<i>123</i>	<i>15.2</i>
EBITDA margin before special items	40.5%	34.9%	
EBIT*	123	104	15.4
<i>Special items</i>	<i>0</i>	<i>0</i>	
<i>EBIT before special items</i>	<i>123</i>	<i>104</i>	<i>15.4</i>
Gross cash flow*	102	87	14.7
Net cash flow*	(61)	(125)	104.9

* for definition see
Bayer Group
Key Data on
page 2

Table of Contents

Interim Report as of March 31, 2007

Bayer MaterialScience

The **MaterialScience** subgroup got off to a good start in 2007, expanding its business once again. **Sales** rose by 4.9 percent to 2,608 million (Q1 2006: 2,486 million), or by 9.4 percent on a currency-adjusted basis. Growth was mainly the result of higher volumes in all segments and regions. We also succeeded in holding selling prices steady overall in the face of continuing strong price pressure.

ebitda before special items did not reach the high level of the previous year, coming in at 409 million (Q1 2006:

539 million). We did not succeed in compensating for the approximately 140 million increase in raw material and energy costs through higher volumes. **ebit** before special items fell by 132 million, or 31.2 percent, to 291 million. After special items, first-quarter ebit declined by 26 million, or 8.4 percent, to 285 million. Earnings of the Systems segment in the prior-year quarter were diminished by one-time expenses of 112 million arising from an arbitration proceeding in the United States concerning the production of propylene oxide.

Materials

Sales in the **Materials** segment advanced by 4.1 percent to 739 million, or by 9.0 percent on a currency-adjusted basis. The Polycarbonates business unit, with sales of 683 million, saw a currency-adjusted 9.1 percent increase in business despite lower selling prices. Volumes advanced in all regions. Sales of the Thermoplastic Polyurethanes business unit moved ahead 8.0 percent when adjusted for currency changes, thanks largely to higher volumes in Europe.

First-quarter **ebitda** before special items dropped by 90 million, or 52.9 percent, to 80 million, with higher volumes not fully offsetting selling price erosion and raw material cost increases. **ebit** fell by 71.2 percent to 38 million.

Systems

Sales of our **Systems** segment in the first quarter gained 5.2 percent from the prior-year period, to 1,869 million. Currency-adjusted sales improved by a substantial 9.6 percent.

Thanks to price increases and volume gains, our Polyurethanes business unit improved sales by 5.0 percent to 1,332 million. Adjusted for shifts in currency parities, growth came to 9.7 percent. The Coatings, Adhesives, Sealants business unit saw sales advance by 6.5 percent. The currency-adjusted increase amounted to 10.3 percent. Here, too, price increases and higher volumes were contributory factors.

ebitda before special items of our Systems segment was down by 40 million, or 10.8 percent, from the excellent level of the prior-year period, to 329 million. Although we almost completely absorbed the increase in raw material costs by raising prices and boosting volume sales, earnings were weighed down by other factors, including the problems experienced by our supplier of raw mdi in Shanghai. **ebit** before special items fell by 38 million, or 13.1 percent, to 253 million. The closure of our mdi plant at New Martinsville, West Virginia, United States, led to 6 million in special charges for the first quarter. After special items, ebit rose by 68 million, or 38.0 percent, to 247 million.

Table of Contents

Interim Report as of March 31, 2007

Bayer MaterialScience million	1st Quarter 2006	1st Quarter 2007	Change %
Net sales	2,486	2,608	+ 4.9
EBITDA*	427	409	4.2
<i>Special items</i>	<i>(112)</i>	<i>0</i>	
<i>EBITDA before special items</i>	<i>539</i>	<i>409</i>	<i>24.1</i>
EBITDA margin before special items	21.7%	15.7%	
EBIT*	311	285	8.4
<i>Special items</i>	<i>(112)</i>	<i>(6)</i>	
<i>EBIT before special items</i>	<i>423</i>	<i>291</i>	<i>31.2</i>
Gross cash flow*	317	304	4.1
Net cash flow*	273	37	86.4

2006 figures restated

* for definition see Bayer Group Key Data on page 2

Materials million	1st Quarter 2006	1st Quarter 2007	Change %
Net sales	710	739	+ 4.1
Polycarbonates	656	683	+ 4.1
Thermoplastic Polyurethanes	54	56	+ 3.7
EBITDA*	170	80	52.9
<i>Special items</i>	<i>0</i>	<i>0</i>	
<i>EBITDA before special items</i>	<i>170</i>	<i>80</i>	<i>52.9</i>
EBITDA margin before special items	23.9%	10.8%	
EBIT*	132	38	71.2
<i>Special items</i>	<i>0</i>	<i>0</i>	
<i>EBIT before special items</i>	<i>132</i>	<i>38</i>	<i>71.2</i>
Gross cash flow*	126	69	45.2
Net cash flow*	35	(25)	

2006 figures restated

* for definition see Bayer Group Key Data on page 2

Systems million	1st Quarter 2006	1st Quarter 2007	Change %
--------------------	------------------------	------------------------	-------------

Net sales	1,776	1,869	+ 5.2
Polyurethanes	1,269	1,332	+ 5.0
Coatings, Adhesives, Sealants	369	393	+ 6.5
Inorganic Basic Chemicals	106	106	0.0
Others	32	38	+ 18.8
EBITDA*	257	329	+ 28.0
<i>Special items</i>	<i>(112)</i>	<i>0</i>	
<i>EBITDA before special items</i>	<i>369</i>	<i>329</i>	<i>10.8</i>
EBITDA margin before special items	20.8%	17.6%	
EBIT*	179	247	+ 38.0
<i>Special items</i>	<i>(112)</i>	<i>(6)</i>	
<i>EBIT before special items</i>	<i>291</i>	<i>253</i>	<i>13.1</i>
Gross cash flow*	191	235	+ 23.0
Net cash flow*	238	62	73.9

* for definition see Bayer Group Key Data on page 2

Table of Contents**Interim Report as of March 31, 2007****Performance by Region**

Bayer's global business expanded in the first quarter of 2007 by 1,544 million, or 22.7 percent, to 8,335 million. Adjusted for shifts in exchange rates, sales rose by 27.3 percent. The increase in sales was mainly due to the inclusion of Schering, Berlin, Germany. The strongest percentage gains were recorded in the Europe and Latin America/Africa/Middle East regions. Adjusted for both currency and portfolio effects, business expanded by 7.5 percent.

The largest increases in absolute terms were achieved in **Europe**, where sales rose by 830 million, or 27.5 percent, to 3,848 million. Europe thus accounted for 46 percent of Group sales in the first quarter, with all subgroups posting a year-on-year improvement. Adjusted for currency and portfolio changes, business grew by 8.4 percent, mainly as a result of substantial increases in the Crop Protection and Systems segments. Sales in Germany climbed by 16.7 percent to 1,301 million, or by 5.0 percent when adjusted for portfolio changes.

Sales in **North America** advanced by 15.0 percent to 2,226 million in the first quarter of 2007, or by 2.7 percent when adjusted for currency and portfolio changes. The Consumer Health segment in North America developed particularly well. The CropScience and MaterialScience subgroups, however, saw sales decline in this region.

In **Asia/Pacific** we expanded business by 19.3 percent, or by 10.1 percent when adjusted for currency and portfolio changes. Sales growth at Bayer HealthCare on a currency- and portfolio-adjusted basis was particularly due to gains in the Consumer Health segment. Sales of CropScience remained nearly steady in this region, dipping by 0.9 percent on a currency-adjusted basis, while MaterialScience posted substantial growth, with currency-adjusted sales up 20.4 percent.

Sales in the **Latin America/Africa/Middle East** region climbed by 27.7 percent, or by 12.9 on a currency- and portfolio-adjusted basis. CropScience sales in this region improved considerably, with a currency-adjusted 20.6 percent gain due primarily to a very pleasing uptrend in the crop protection business. We also generated higher sales in the HealthCare and MaterialScience subgroups.

Sales by Region and Segment (by Market) million	Europe				North America			
	1st	1st	% adj.	% adj.	1st	1st	% adj.	% adj.
	Quarter 2006	Quarter 2007			Quarter 2006	Quarter 2007		
HealthCare	883	1,495	+ 69.3	+ 69.1	696	1,145	+ 64.5	+ 79.3
Pharmaceuticals	449	1,039	+ 131.4	+ 130.8	356	754	+ 111.8	+ 130.7
Consumer Health	434	456	+ 5.1	+ 5.1	340	391	+ 15.0	+ 25.4
CropScience	766	862	+ 12.5	+ 12.3	538	447	16.9	9.2
Crop Protection	623	723	+ 16.1	+ 16.0	380	292	23.2	16.1
Environmental Science, BioScience	143	139	2.8	3.3	158	155	1.9	+ 7.4
MaterialScience	1,065	1,185	+ 11.3	+ 11.3	700	631	9.9	1.6
Materials	274	283	+ 3.3	+ 3.6	151	149	1.3	+ 7.9
Systems	791	902	+ 14.0	+ 14.0	549	482	12.2	4.2
Continuing operations (incl. reconciliation)	3,018	3,848	+ 27.5	+ 27.5	1,936	2,226	+ 15.0	+ 25.4

Sales by Region and Segment (by Market)	Asia/Pacific				Latin America/Africa/Middle East			
	1st	1st	% adj.	% adj.	1st	1st	% adj.	% adj.
	Quarter 2006	Quarter 2007			Quarter 2006	Quarter 2007		

				adj. %				
million								
HealthCare	308	466	51.3	62.5	316	504	+ 59.5	+ 75.7
Pharmaceuticals	224	379	69.2	82.7	119	323	+ 171.4	+ 196.7
Consumer Health	84	87	+ 3.6	+ 8.6	197	181	8.1	+ 2.6
CropScience	236	219	7.2	0.9	231	258	+ 11.7	+ 20.6
Crop Protection	207	189	8.7	2.4	203	230	+ 13.3	+ 21.7
Environmental Science, BioScience	29	30	+ 3.4	10.4	28	28	0.0	+ 12.5
MaterialScience	450	506	12.4	20.4	271	286	+ 5.5	+ 12.2
Materials	219	240	+ 9.6	17.5	66	67	+ 1.5	+ 5.9
Systems	231	266	15.2	23.1	205	219	+ 6.8	+ 14.2
Continuing operations (incl. reconciliation)	1,006	1,200	19.3	27.8	831	1,061	+ 27.7	+ 38.7

Sales by Region and Segment (by Market)	1st Quarter 2006	Continuing Operations		adj. %
		1st Quarter 2007	%	
million				
HealthCare	2,203	3,610	+63.9	+ 69.2
Pharmaceuticals	1,148	2,495	+117.3	+ 122.2
Consumer Health	1,055	1,115	+5.7	+ 11.4
CropScience	1,771	1,786	+0.8	+ 5.1
Crop Protection	1,413	1,434	+1.5	+ 5.5
Environmental Science, BioScience	358	352	1.7	+ 3.7
MaterialScience	2,486	2,608	+4.9	+ 9.4
Materials	710	739	+4.1	+ 9.0
Systems	1,776	1,869	+5.2	+ 9.6
Continuing operations (incl. reconciliation)	6,791	8,335	+22.7	+ 27.3

2006 figures restated; adj. = currency-adjusted

Table of Contents**Interim Report as of March 31, 2007****Liquidity and Capital Resources****Operating cash flow**

Gross cash flow in the first quarter of 2007 amounted to 1,411 million, up 29.6 percent from the prior-year quarter (1,089 million). The increase was mainly due to the inclusion of Schering, Berlin, Germany, and the strong performance of the business. Net cash flow improved by 337 million to 375 million Q1 2006: 38 million). The change in working capital improved slightly compared with the first quarter of 2006 despite the growth in business.

Bayer Group Summary Cash Flow Statements million	1st Quarter 2006	1st Quarter 2007
Gross cash flow*	1,089	1,411
Changes in working capital/other non-cash items	(1,051)	(1,036)
Net cash provided by (used in) operating activities (net cash flow), continuing operations	38	375
Net cash provided by (used in) operating activities (net cash flow), discontinued operations	90	38
Net cash provided by (used in) operating activities (net cash flow) (total)	128	413
Net cash provided by (used in) investing activities (total)	(192)	4,589
Net cash provided by (used in) financing activities (total)	(187)	(1,764)
Change in cash and cash equivalents due to business activities (total)	(251)	3,238
Cash and cash equivalents, January 1	3,290	2,915
Change due to exchange rate movements and to changes in scope of consolidation	(13)	(10)
Cash and cash equivalents, March 31	3,026	6,143

2006 figures
restated

* for definition
see Bayer
Group Key Data
on page 2

Investing cash flow

There was a net cash inflow of 4,589 for investing activities in the first three months of 2007, compared with a 192 million outflow in the prior-year quarter. The main items here are net proceeds totaling 4.7 billion from the divestments of our Diagnostics business and H.C. Starck. In January 2007 we sold the Diagnostics business to Siemens for 4.3 billion. Following an initial receipt of 0.4 billion in December 2006, there was a further inflow of 3.7 billion (after deducting divested cash of approximately 0.2 billion) from this transaction at the beginning of 2007. In subsequent quarters we will pay approximately 0.6 billion in taxes on the divestment gain. We sold H.C. Starck to Advent International and The Carlyle Group for approximately 1.2 billion. The transaction volume is comprised mainly of a cash component including compensation for financial liabilities of more than 0.9 billion, along with the assumption of 0.2 billion in pension obligations. This sale was closed at the beginning of February 2007.

Table of Contents**Interim Report as of March 31, 2007**

Cash outflows for property, plant and equipment (193 million) and intangible assets (8 million) totaled 201 million (Q1 2006: 419 million). The prior-year figure included in particular the purchase of the European marketing rights for the blood pressure treatments Pritor® and PritorPlus® and expenditures for the expansion of our polymers production facilities in Caojing, China.

Financing cash flow

The 1,764 million (Q1 2006: 187 million) cash outflow for financing activities comprised 245 million in interest payments, 1,510 million in net repayments of loans and 9 million for dividend payments to minority stockholders of consolidated companies. The item Bayer AG dividend in the prior-year period contained an inflow of 176 million from the reimbursement of advance capital gains tax payments made on intragroup dividends in 2004.

As of March 31, 2007 the Bayer Group had cash and cash equivalents of 6,143 million, including 784 million held in escrow accounts. The latter amount comprises 699 million deposited in a guarantee account following the decision by the Extraordinary Stockholders Meeting of Bayer Schering Pharma AG on January 17, 2007 to squeeze out Bayer Schering Pharma AG's remaining minority stockholders. The decision means the shares still held by minority stockholders will be transferred to the main stockholder, Bayer Schering GmbH, a wholly owned subsidiary of Bayer AG, in return for cash compensation of 98.98 per share. Dissenting stockholders are seeking to have the stockholder resolution set aside or to have it declared null and void. An additional 85 million is earmarked for payments relating to civil law settlements in antitrust proceedings.

In view of the restriction on its use, the liquidity held in escrow accounts was not deducted when calculating net debt. The high level of cash and cash equivalents will return to normal in subsequent quarters, particularly following the redemption of bonds.

Liquid assets and net debt

Net debt (total) declined by 4.8 billion compared with December 31, 2006, to 12.8 billion. This was due particularly to cash inflows from the divestitures and to the improvement in operating cash flow. We intend to use the proceeds of the planned sale of Wolff Walsrode to The Dow Chemical Company to further reduce net debt.

Net Debt

million	Dec. 31, 2006	March 31, 2007
Noncurrent financial liabilities as per balance sheets (including derivatives)	14,723	14,626
of which mandatory convertible bond	2,276	2,278
of which hybrid bond	1,247	1,245
Current financial liabilities as per balance sheets (including derivatives)	5,078	3,673
Derivative receivables	(185)	(165)
Financial liabilities	19,616	18,134
Cash and cash equivalents*	(2,116)	(5,359)
Current financial assets	(27)	(5)
Net debt from continuing operations	17,473	12,770
Net debt from discontinued operations	66	7
Net debt (total)	17,539	12,777

* In view of the restriction on its use, the 784 million liquidity in escrow accounts in the first

quarter of 2007

(Q1 2006:

299 million)

was not

deducted when

calculating net

debt. March 31,

2007:

5,359 million =

6,143 million

784 million

(Dec. 31, 2006:

2,116 million =

2,915 million

799 million).

Table of Contents

Interim Report as of March 31, 2007

As of March 31, 2007 we had noncurrent financial liabilities of 14.6 billion, including the 1.2 billion hybrid bond issued in July 2005 and the 2.3 billion mandatory convertible bond issued in April 2006. Moody's and Standard & Poor's treat 75 percent and 50 percent, respectively, of the hybrid bond as equity. Both rating agencies consider the mandatory convertible bond wholly as equity. Unlike conventional borrowings, the hybrid bond thus has only a limited effect on the Group's rating-specific debt indicators, while the mandatory convertible bond has no effect. Standard & Poor's gives Bayer AG a long-term issuer rating of bbb+ with positive outlook, while Moody's gives the company a rating of A3 with negative outlook. The short-term ratings are A-2 (Standard & Poor's) and P-2 (Moody's). These investment-grade ratings evidence a continuing high level of creditworthiness.

Employees

The number of employees is shown as full-time equivalents, which means part-time employees are included in proportion to their contractual working hours. We believe this presentation improves the comparability of personnel expenses and employee numbers. The previous year's data have been restated accordingly.

On March 31, 2007 the Bayer Group had 105,100 employees, a decline of 1.0 percent compared to December 31, 2006. The number of employees thus remained virtually steady. Personnel expenses increased by 27.7 percent to 1,898 million (Q1 2006: 1,486 million), mainly due to the inclusion of personnel expenses for the employees of the former Schering group.

In the individual regions, too, the number of employees was practically unchanged against December 31, 2006. Compared to the previous year, the size of the workforce increased significantly, primarily due to the inclusion of the employees of the former Schering group. We currently employ 16,700 people in North America, 17,800 in Asia/Pacific, 13,800 in Latin America/Africa/Middle East and 56,800 in Europe. Our 40,000 employees in Germany account for 38.1 percent of the Group total.

Table of Contents

Interim Report as of March 31, 2007

Legal Risks

As a global company with a diverse business portfolio, the Bayer Group is exposed to various legal risks. Legal proceedings currently considered to involve material risks are outlined below. The litigation referred to does not necessarily represent an exhaustive list.

Lipobay/Baycol:

As of April 20, 2007, the number of Lipobay/Baycol cases pending against Bayer worldwide was approximately 1,230 (approximately 1,175 of them in the United States, including several class actions). At the same date, Bayer had settled 3,160 Lipobay/Baycol cases worldwide without acknowledging any liability and resulting in settlement payments of approximately us\$ 1,162 million. In the United States five cases have been tried to date, all of which were found in Bayer's favor.

After more than five years of litigation we are currently aware of fewer than 20 pending cases in the United States that in our opinion hold a potential for settlement, although we cannot rule out the possibility that additional cases involving serious side effects from Lipobay/Baycol may come to our attention. In addition, there could be further settlements of cases outside of the United States.

Since the existing insurance coverage with respect to the Lipobay/Baycol cases is exhausted, it is possible depending on the future progress of the litigation that Bayer could face further payments that are not covered by the accounting measures already taken. We will regularly review the possibility of further accounting measures depending on the progress of the litigation.

Cipro®:

39 putative class action lawsuits and one individual lawsuit against Bayer involving the medication Cipro® have been pending since July 2000 in the United States. The plaintiffs are suing Bayer and other companies also named as defendants, alleging that a settlement reached in 1997 to end litigation between Bayer and Barr Laboratories, Inc. concerning the validity of a Cipro® patent violated antitrust regulations. The plaintiffs claim the alleged violation prevented the marketing of generic ciprofloxacin since 1997. Plaintiffs also are seeking triple damages under u.s. law. After the settlement with Barr, the Cipro® patent was the subject of a successful re-examination by the u.s. Patent and Trademark Office and of successful defenses in u.s. federal courts. The patent has since expired.

In March 2005, a federal district court in New York granted summary judgment in favor of Bayer in all actions pending in federal court. The plaintiffs are appealing this decision. Further cases are pending before various state courts. Bayer believes that it has meritorious defenses and intends to defend these cases vigorously.

Table of Contents

Interim Report as of March 31, 2007

Medrad:

As reported in the past, Liebel-Flarsheim Company and its parents, Mallinckrodt, Inc. and Tyco Healthcare Group Ip, filed suit against Bayer's u.s. subsidiary Medrad alleging that some of Medrad's front load syringe injectors infringe patents held by Liebel-Flarsheim. In March 2007, the u.s. Court of Appeals decided that the Liebel-Flarsheim patents are invalid. Bayer believes that the legal risks involved in these proceedings are no longer material for the Bayer Group.

Yasmin®/yaz®:

In April 2005, Schering AG (now Bayer Schering Pharma AG), Berlin, Germany, filed an and a iv suit against Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc. in u.s. federal court alleging patent infringement by Barr for its generic version of Bayer Schering Pharma's Yasmin® oral contraceptive product in the United States. In June, 2005, Barr filed its counterclaims seeking to invalidate Bayer Schering Pharma's patent.

In January 2007, Schering received notice from Barr Laboratories, Inc. that it has filed an and a iv application with the u.s. fda seeking approval of a generic version of Schering's ya® oral contraceptive product. Barr will be prohibited from marketing its generic version until after expiry in March 2009 of the three-year exclusivity period for marketing granted by the fda.

The Company highly values its Yasmin® and yaz® oral contraceptive products and is deeply committed to continuing its leadership position in oral contraception.

llrice:

Since August 2006 numerous lawsuits, including putative class actions, have been filed by rice farmers, distributors and rice mills against Bayer CropScience Ip in the United States. The plaintiffs are suing the company, alleging that they have suffered economic losses after traces of the genetically modified rice event from the Liberty Link rice lines (llrice) were identified in samples of conventional long-grain rice grown in the u.s. This is alleged to have led in particular to a decline in the commodity price for long-grain rice due to import restrictions imposed by the European Commission and certain other countries. After development, llrice 601 was further tested in cooperation with third parties, including a breeding institute in the u.s. However, it was never selected for commercialization.

In March 2007 traces of llrice 62 and llrice 604 were found in Clearfield 131 conventional hybrid rice marketed by basf. Subsequently the usda issued an order temporarily prohibiting the sale or planting of Clearfield 131.

Table of Contents

Interim Report as of March 31, 2007

The usda and the fda have stated that llrice 62, 601 and 604 do not constitute a health risk and are safe for use in food and feed and for the environment. The usda deregulated llrice 62 in 1999 and, upon Bayer CropScience's application, deregulated ll rice 601 in November 2006.

Bayer believes it has meritorious defenses and intends to defend these cases vigorously.

Rubber, polyester polyols, urethane: Proceedings involving the former rubber-related lines of business

A number of investigations and proceedings by the respective authorities in the e.u. and Canada for alleged anticompetitive conduct involving certain products in the rubber field have been resolved, while others remain pending. As previously reported, in the United States the investigations of the u.s. Department of Justice into Bayer's conduct have been concluded. In November 2006, the e.u. Commission closed the proceedings related to br/esbr by imposing fines against several companies and granting full amnesty to Bayer.

Numerous civil claims for damages including class actions are pending in the United States and Canada against Bayer AG and certain of its subsidiaries as well as other companies. The lawsuits involve rubber chemicals, epdm, nbr and polychloroprene rubber (cr). As previously reported, Bayer has settled the actions which management believes to be material.

Proceedings involving polyester polyols, urethanes and urethane chemicals

As previously reported, Bayer has resolved the u.s. Department of Justice investigation previously pending in the United States. In Canada an investigation is pending against Bayer for alleged anticompetitive conduct relating to adipic-based polyester polyols.

A number of civil claims for damages, including class actions, have been filed against Bayer in the United States involving allegations of unlawful collusion on prices for certain polyester polyols, urethanes and urethane chemicals product lines. Similar actions are pending in Canada with respect to polyester polyols. Bayer has settled several actions pending in the United States. These settlements do not resolve all of the pending civil litigation nor do they preclude the bringing of additional claims.

Proceedings involving polyether polyols and other precursors for urethane end-use products

Bayer has been named as a defendant in multiple putative class action lawsuits in the United States and Canada involving allegations of price fixing for, inter alia, polyether polyols and certain other precursors for urethane end-use products. In the United States, Bayer has settled with a class of direct purchasers of polyether polyols, mdi and tdi (and related systems) representing approximately 75 percent of the purchases, which settlement has been approved by the court. The remaining direct purchasers opted out of the settlement and have the right to bring their own actions. To date no such actions have been brought. In Canada, the class action lawsuit on behalf of direct and indirect purchasers of polyether polyols, mdi and tdi (and related systems) continues. In February 2006 Bayer was served with a subpoena from the u.s. Department of Justice seeking information relating to the manufacture and sale of these products.

Table of Contents

Interim Report as of March 31, 2007

Impact of antitrust proceedings on Bayer

Excluding the portion allocated to Lanxess, the provision with respect to the described civil proceedings were reduced from 285 million in 2005 to 124 million as of March 31, 2007, due to settlement payments.

Bayer will continue to pursue settlements that in its view are warranted. In cases where settlement is not achievable, Bayer will continue to defend itself vigorously.

The financial risk associated with the proceedings described above beyond the amounts already paid and the financial provisions already established is currently not quantifiable due to the considerable uncertainty associated with these proceedings. Consequently, no provisions other than those described above have been established. The Company expects that, in the course of the regulatory proceedings and civil damages suits, additional charges will become necessary.

Arbitration proceeding concerning propylene oxide

As previously reported, an arbitration panel in May 2006 issued a final award in favor of Lyondell Chemical Co. in respect of a dispute with Bayer over interpretation of their joint venture agreements for the manufacture of propylene oxide. Bayer was seeking to vacate the final award, while Lyondell was seeking to confirm the award as well as obtain pre-award interest. On March 20, 2007, the Texas District Court denied Bayer's motion to vacate, confirmed in part the final award and ordered additional discovery relevant to one issue on which confirmation was not granted. Bayer has established appropriate provisions for the entire matter. In January 2007, Bayer filed a suit against Lyondell in the Delaware State Court of Chancery, seeking equitable reformation of one of the license agreements relating to the joint venture and restitution of certain monies paid or allegedly owing by Bayer to Lyondell.

Subsequent Events

In April 2007 the Japanese Ministry of Health, Labor and Welfare (mhlw) approved the novel cholesterol-lowering agent zetia® (ezetimibe). zetia® will be co-marketed by Bayer Yakuhin Ltd. and Schering-Plough K.K. Japan. The drug is approved for use either as mono-therapy or co-administered with a statin, for further reduction of ldl (bad) cholesterol.

The co-marketing agreement regarding zetia® in Japan is part of Bayer's strategic pharmaceuticals alliance with Schering-Plough, which was announced in 2004. Bayer's primary care pharmaceutical products, such as the antibiotics Avelox® and Cipro®, the cardiovascular product Adalat® and also Levitra® are today marketed and distributed by Schering-Plough in the United States and Puerto Rico.

Please note that Bayer Schering Pharma AG is not legally related to Schering-Plough Corporation, New Jersey, United States. The two companies have been totally independent of each other for many years.

Table of Contents**Interim Report as of March 31, 2007****Calculation of ebit(da) Before Special Items**

ebitda, ebitda before special items and ebit before special items are not defined in the International Financial Reporting Standards and should therefore be regarded only as supplementary information. The company considers the underlying earnings figures to be more suitable indicators of operating performance since they are not affected by special items, and ebitda before special items is not affected by depreciation, amortization or write-downs/write-backs. The company also believes that these indicators give readers a clearer picture of the results of operations and ensure greater comparability of data over time.

	EBIT	EBIT	EBITDA	EBITDA
	1st	1st	1st	1st
Special Items Reconciliation	Quarter	Quarter	Quarter	Quarter
million	2006	2007	2006	2007
After special items	1,049	1,175	1,436	1,774
HealthCare	6	139	6	165
Schering PPA effects*	0	20	0	64
Schering integration costs	0	119	0	101
Litigation	5	0	5	0
Other	1	0	1	0
CropScience	0	39	0	36
Restructuring	0	39	0	36
MaterialScience	112	6	112	0
Restructuring	0	6	0	0
Litigation	112	0	112	0
Reconciliation	10	16	10	15
Restructuring Industry Services	0	16	0	15
Litigation	10	0	10	0
Total special items	128	200	128	216
Before special items	1,177	1,375	1,564	1,990

* The purchase price paid for Schering AG, Germany, was allocated among the acquired assets and assumed liabilities in accordance with the International Financial Reporting Standards (IFRS). The purchase price allocation, which is not yet

complete,
resulted in total
charges to ebit
of 224 million
in the first
quarter of 2007.

To ensure
comparability
with future
earnings data,
the expected
long-term
effects of the
step-up are
reflected in ebit
and ebitda
before special
items, whereas
temporary,
non-cash effects
of the purchase
price allocation
are eliminated.

When
calculating
EBIT before
special items,
we deducted a
20 million
special charge
recorded in this
connection. ebit
before special
items therefore
reflects

204 million in
charges
resulting from
the purchase
price allocation.
ebitda before
special items
remains
unaffected by
the purchase
price allocation.

Table of Contents**Investor Information**

Bayer stock performed very well in the first quarter of 2007, ending the quarter at 47.84, up 17.7 percent from the closing price on December 31, 2006. This was the highest closing price for Bayer stock in the past five years. Over the same period the dax rose 4.9 percent to 6,917.

Supported by a favorable market environment, this outstanding performance was due to the good results for fiscal 2006 and our positive business outlook, which in turn led to a number of upgrades by financial analysts.

Bayer Stock Key Data	1st Quarter 2006	1st Quarter 2007	Full Year 2006	
High for the period ()	36.37	47.84	40.92	
Low for the period ()	31.70	40.20	30.56	
Average daily share turnover on German stock exchanges (million)	5.6	5.5	5.6	
				Change March 31, 2007/ Dec. 31, 2006 %
	March 31, 2006	March 31, 2007	Dec. 31, 2006	
Share price ()	33.06	47.84	40.66	17.7
Market capitalization (million)	24,145	36,566	31,078	17.7
Stockholders' equity (million)	12,105	15,906	12,851	23.8
Number of shares entitled to the dividend (million)	730.34	764.34	764.34	0.0
DAX	5,970	6,917	6,597	4.9

XETRA closing price; source: Bloomberg

Performance of Bayer Stock

Index (100 = xetra closing price on December 31, 2005)

Table of Contents**Interim Report as of March 31, 2007****Calculation of core earnings per share**

Earnings per share according to ifrs are affected by the purchase price allocation and other special factors. To enhance comparability, we also determine core net income from continuing operations after elimination of the amortization of intangible assets, asset write-downs (including any impairment losses), special items in ebitda and extraordinary factors affecting income from investments in affiliated companies (such as divestment gains or write-downs), including the related tax effects.

The calculation of earnings per share in accordance with ifrs is explained in the notes to this interim report on page 37. Adjusted core net income, core earnings per share and core ebit are not defined in the International Financial Reporting Standards. Therefore they should be regarded as supplementary information rather than stand-alone indicators.

	1st Quarter 2006	1st Quarter 2007
Calculation of Core EBIT and Core Earnings per Share		
million		
EBIT as per income statement	1,049	1,175
Amortization and write-downs of intangible assets	131	293
Write-downs of property, plant and equipment	6	24
Special items (other than write-downs)	128	216
Core EBIT	1,314	1,708
Non-operating result (as per income statement)	(210)	(218)
Extraordinary income/loss from investments in affiliated companies		
Income taxes (as per income statement)	(277)	(301)
Tax adjustment	(93)	(177)
Income after taxes attributable to minority interest (as per income statement)	3	(1)
Core net income from continuing operations	737	1,011
Financing expenses for the mandatory convertible bond, net of tax effects		24
Adjusted core net income	737	1,035
Shares		
Weighted average number of issued ordinary shares	730,341,920	764,341,920
Potential shares to be issued upon conversion of the mandatory convertible bond		59,523,810
Adjusted weighted average total number of issued and potential ordinary shares	730,341,920	823,865,730
Core earnings per share from continuing operations ()	1.01	1.26

Table of Contents

Interim Report as of March 31, 2007

Bayer Group Consolidated Statements of Income

million	1st Quarter 2006	1st Quarter 2007
Net sales	6,791	8,335
Cost of goods sold	(3,438)	(4,134)
Gross profit	3,353	4,201
Selling expenses	(1,365)	(1,807)
Research and development expenses	(414)	(625)
General administration expenses	(353)	(436)
Other operating income	208	143
Other operating expenses	(380)	(301)
Operating result (EBIT)	1,049	1,175
Equity-method loss	(8)	(14)
Non-operating income	350	242
Non-operating expenses	(552)	(446)
Non-operating result	(210)	(218)
Income before income taxes	839	957
Income taxes	(277)	(301)
Income from continuing operations after taxes	562	656
Income from discontinued operations after taxes	35	2,154
Income after taxes	597	2,810
<i>of which attributable to minority interest</i>	<i>(3)</i>	<i>1</i>
<i>of which attributable to Bayer AG stockholders (net income)</i>	<i>600</i>	<i>2,809</i>
Earnings per share ()		
From continuing operations		
Basic*	0.77	0.82
Diluted*	0.77	0.82
From continuing and discontinued operations		
Basic*	0.82	3.44
Diluted*	0.82	3.44

2006 figures
restated

* The ordinary
shares to be
issued upon

conversion of
the mandatory
convertible
bond are treated
as already
issued shares.

Table of Contents**Interim Report as of March 31, 2007****Bayer Group Consolidated Balance Sheets**

million	March 31, 2006	March 31, 2007	Dec. 31, 2006
Noncurrent assets			
Goodwill	2,546	8,183	8,227
Other intangible assets	4,656	15,448	15,807
Property, plant and equipment	7,339	8,740	8,867
Investments in associates	776	517	532
Other financial assets	1,227	1,177	1,094
Other receivables	140	184	165
Deferred taxes	1,301	1,005	1,205
	17,985	35,254	35,897
Current assets			
Inventories	4,774	6,327	6,153
Trade accounts receivable	5,436	6,759	5,802
Other financial assets	526	238	401
Other receivables	1,403	1,356	1,217
Claims for tax refunds	446	550	581
Cash and cash equivalents	3,026	6,143	2,915
Assets held for sale and discontinued operations	2,832	346	2,925
	18,443	21,719	19,994
Total assets	36,428	56,973	55,891
Stockholders' equity			
Capital stock of Bayer AG	1,870	1,957	1,957
Capital reserves of Bayer AG	2,942	4,028	4,028
Other reserves	7,222	9,855	6,782
	12,034	15,840	12,767
Equity attributable to minority interest	71	66	84
	12,105	15,906	12,851
Noncurrent liabilities			
Provisions for pensions and other post-employment benefits	5,961	6,156	6,543
Other provisions	1,670	1,506	1,464
Financial liabilities	7,418	14,626	14,723
Other liabilities	469	402	449
Deferred taxes	293	4,397	4,346
	15,811	27,087	27,525
Current liabilities			
Other provisions	2,809	4,571	3,765
Financial liabilities	1,309	3,673	5,078
Trade accounts payable	1,610	2,289	2,369
Tax liabilities	283	463	400

Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

Other liabilities	1,608	2,826	3,055
Liabilities directly related to assets held for sale and discontinued operations	893	158	848
	8,512	13,980	15,515
Total stockholders' equity and liabilities	36,428	56,973	55,891

2006 figures restated

32

Table of Contents

Interim Report as of March 31, 2007

Bayer Group**Consolidated Statements of Cash Flows**

million	1st Quarter 2006	1st Quarter 2007
Income from continuing operations after taxes	562	656
Income taxes	277	301
Non-operating result	210	218
Income taxes paid	(216)	(343)
Depreciation and amortization	387	599
Change in pension provisions	(130)	(96)
(Gains) losses on retirements of noncurrent assets	(1)	12
Non-cash effects of the remeasurement of acquired assets (inventory work-down)		64
Gross cash flow	1,089	1,411
Decrease (increase) in inventories	(114)	(213)
Decrease (increase) in trade accounts receivable	(889)	(1,011)
(Decrease) increase in trade accounts payable	(231)	(114)
Changes in other working capital, other non-cash items	183	302
Net cash provided by (used in) operating activities (net cash flow), continuing operations	38	375
Net cash provided by (used in) operating activities (net cash flow), discontinued operations	90	38
Net cash provided by (used in) operating activities (net cash flow), total	128	413
Cash outflows for property, plant, equipment and intangible assets	(419)	(201)
Cash inflows from sales of property, plant, equipment and other assets	20	18
Cash inflows from divestitures less divested cash	0	4,673
Cash outflows for acquisitions less acquired cash	(20)	(22)
Cash inflows from noncurrent financial assets	26	5
Interest and dividends received	107	93
Cash inflows (outflows) from current financial assets	94	23
Net cash provided by (used in) investing activities (total)	(192)	4,589
Capital contributions	0	0
Bayer AG dividend, dividend payments to minority stockholders, reimbursements of advance capital gains tax payments	165	(9)
Issuances of debt	269	444
Retirements of debt	(393)	(1,954)
Interest paid	(228)	(245)
Net cash provided by (used in) financing activities (total)	(187)	(1,764)
Change in cash and cash equivalents due to business activities (total)	(251)	3,238
Cash and cash equivalents, January 1	3,290	2,915
Change in cash and cash equivalents due to changes in scope of consolidation	(2)	(1)

Change in cash and cash equivalents due to exchange rate movements	(11)	(9)
Cash and cash equivalents, March 31	3,026	6,143

2006 figures
restated

Table of Contents

Interim Report as of March 31, 2007

Bayer Group Consolidated Statements of Recognized Income and Expense

million	1st Quarter 2006	1st Quarter 2007
Changes in fair values of derivatives designated as hedges and available-for-sale financial assets, recognized in stockholders' equity	9	1
Changes in actuarial gains/losses on defined benefit obligations for pensions and other post-employment benefits, recognized in stockholders' equity	805	331
Exchange differences on translation of operations outside the euro zone, recognized in stockholders' equity	(144)	36
Deferred taxes on valuation adjustments offset directly against stockholders' equity	(315)	(134)
Changes due to changes in scope of consolidation		31
Valuation adjustments recognized directly in stockholders' equity	355	265
Income after taxes	597	2,810
Total income and expense recognized in the financial statements	952	3,075
<i>of which attributable to minority interest</i>	(5)	2
<i>of which attributable to Bayer AG stockholders</i>	957	3,073

Table of Contents

Interim Report as of March 31, 2007

Key Data by Segment

million	HealthCare			
	Pharmaceuticals		Consumer Health	
	1st	1st	1st	1st
	Quarter	Quarter	Quarter	Quarter
	2006	2007	2006	2007
Net sales (external)	1,148	2,495	1,055	1,115
Change	+20.6%	+117.3%	+22.0%	+5.7%
Currency-adjusted change	+15.2%	+122.2%	+15.8%	+11.4%
Intersegment sales	13	12	2	3
Operating result (EBIT)	202	281	177	204
Depreciation, amortization and write-downs/write-backs	39	265	41	33
Gross cash flow*	162	390	130	167
Net cash flow*	(11)	279	54	104
Number of employees at end of period	16,700	39,400	11,700	11,500

	Crop Science			
	Crop Protection		Environmental Science, BioScience	
	1st	1st	1st	1st
	Quarter	Quarter	Quarter	Quarter
	2006	2007	2006	2007
Net sales (external)	1,413	1,434	358	352
Change	-0.3%	+1.5%	+9.5%	-1.7%
Currency-adjusted change	-5.8%	+5.5%	+3.4%	+3.7%
Intersegment sales	18	18	2	2
Operating result (EBIT)	285	304	123	104
Depreciation, amortization and write-downs/write-backs	121	121	22	19
Gross cash flow*	285	282	102	87
Net cash flow*	(289)	(113)	(61)	(125)
Number of employees at end of period	15,500	14,900	2,800	2,900

	Material Science			
	Materials		Systems	
	1st	1st	1st	1st
	Quarter	Quarter	Quarter	Quarter
	2006	2007	2006	2007
Net sales (external)	710	739	1,776	1,869
Change	+12.0%	+4.1%	+9.6%	+5.2%
Currency-adjusted change	+6.6%	+9.0%	+4.8%	+9.6%
Intersegment sales	6	4	39	38
Operating result (EBIT)	132	38	179	247

Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

Depreciation, amortization and write-downs/write-backs	38	42	78	82
Gross cash flow*	126	69	191	235
Net cash flow*	35	(25)	238	62
Number of employees at end of period	4,800	4,900	9,800	10,200

	Reconciliation		Continuing Operations	
	1st	1st	1st	1st
	Quarter	Quarter	Quarter	Quarter
	2006	2007	2006	2007
Net sales (external)	331	331	6,791	8,335
Change			+11.4%	+22.7%
Currency-adjusted change			+6.2%	+27.3%
Intersegment sales	(80)	(77)		
Operating result (EBIT)	(49)	(3)	1,049	1,175
Depreciation, amortization and write-downs/write-backs	48	37	387	599
Gross cash flow*	93	181	1,089	1,411
Net cash flow*	72	193	38	375
Number of employees at end of period	21,100	21,300	82,400	105,100

2006 figures
restated

* for definition
see Bayer
Group Key Data
on page 2

Table of Contents

Interim Report as of March 31, 2007

Key Data by Region

million	Europe		North America	
	1st Quarter 2006	1st Quarter 2007	1st Quarter 2006	1st Quarter 2007
Net sales (external) by market	3,018	3,848	1,936	2,226
Change	+6.8%	+27.5%	+20.8	+15.0%
Currency-adjusted change	+6.6%	+27.5%	+9.8	+25.4%
Net sales (external) by point of origin	3,226	4,153	1,952	2,220
Change	+6.9%	+28.7%	+21.2	+13.7%
Currency-adjusted change	+6.8%	+28.7%	+10.0	+24.2%
Interregional sales	1,045	1,374	477	516
Operating result (EBIT)	663	724	262	357
Gross cash flow*	689	1,302	259	(52)
Number of employees at end of period	45,200	56,800	13,000	16,700

	Asia/Pacific		Latin America Africa/Middle East	
	1st Quarter 2006	1st Quarter 2007	1st Quarter 2006	1st Quarter 2007
Net sales (external) by market	1,006	1,200	831	1,061
Change	+7.7%	+19.3%	+13.2%	+27.7%
Currency-adjusted change	+2.2%	+27.8%	+1.6%	+38.7%
Net sales (external) by point of origin	964	1,137	649	825
Change	+7.1%	+17.9%	+14.1%	+27.1%
Currency-adjusted change	+1.4%	+26.9%	-0.4%	+40.8%
Interregional sales	59	53	42	57
Operating result (EBIT)	123	73	44	63
Gross cash flow*	128	98	38	71
Number of employees at end of period	13,600	17,800	10,600	13,800

	Reconciliation		Continuing Operations	
	1st Quarter 2006	1st Quarter 2007	1st Quarter 2006	1st Quarter 2007
Net sales (external) by market			6,791	8,335
Change			+11.4%	+22.7%
Currency-adjusted change			+6.2%	+27.3%
Net sales (external) by point of origin			6,791	8,335
Change			+11.4%	+22.7%

Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

Currency-adjusted change			+6.2%	+27.3%
Interregional sales	(1,623)	(2,000)		
Operating result (EBIT)	(43)	(42)	1,049	1,175
Gross cash flow*	(25)	(8)	1,089	1,411
Number of employees at end of period			82,400	105,100

2006 figures
restated

* for definition
see Bayer
Group Key Data
on page 2

Table of Contents**Interim Report as of March 31, 2007****Notes to the Interim Report as of March 31, 2007****Accounting policies**

Pursuant to Section 315a of the German Commercial Code, the unaudited consolidated interim financial statements as of March 31, 2007 have been prepared according to the International Financial Reporting Standards (ifrs) including ias 34 of the International Accounting Standards Board (iasb), London, which are endorsed by the European Union, and the Interpretations of the International Financial Reporting Interpretations Committee (ifric), in effect at the closing date.

Reference should be made as appropriate to the notes to the 2006 financial statements, particularly with regard to recognition and valuation principles.

Information on earnings per share

The ordinary shares to be issued upon conversion of the mandatory convertible bond are treated as already issued shares. Diluted earnings per share are therefore equal to basic earnings per share.

Calculation of Earnings per Share

million	1st Quarter 2006	1st Quarter 2007
Income after taxes	597	2,810
Income attributable to minority interest	(3)	1
Income attributable to Bayer AG stockholders	600	2,809
Income from discontinued operations	35	2,154
Financing expenses for the mandatory convertible bond, net of tax effects		24
Adjusted income after taxes from continuing operations	565	679
Adjusted net income	600	2,833
Weighted average number of issued ordinary shares	730,341,920	764,341,920
Potential shares to be issued upon conversion of the mandatory convertible bond		59,523,810
Adjusted weighted average total number of issued and potential ordinary shares	730,341,920	823,865,730
Basic earnings per share ()		
from continuing operations	0.77	0.82
from continuing and discontinued operations	0.82	3.44
Diluted earnings per share ()		
from continuing operations	0.77	0.82
from continuing and discontinued operations	0.82	3.44

2006 figures
restated

Changes in the Bayer Group***Scope of consolidation***

As of March 31, 2007, the Bayer Group comprised 386 fully or proportionately consolidated companies, compared with 432 companies as of December 31, 2006. This decrease is primarily the result of companies leaving the group through the Diagnostics and H.C. Starck divestitures and of intragroup mergers of companies as part of the integration of Schering, Berlin, Germany.

Table of Contents**Interim Report as of March 31, 2007****Discontinued operations**

In mid-2006 Bayer AG and Siemens AG signed an agreement concerning the sale of the Diagnostics business, which was transferred to the new owner on January 2, 2007.

On November 23, 2006 an agreement was concluded to divest the activities of the H.C. Starck group, formerly assigned to the Materials segment, to a consortium of two financial investors, Advent International and The Carlyle Group. This business was transferred to the new owners on February 1, 2007.

The agreement to sell the companies of the Wolff Walsrode group, which operates principally in the field of cellulose chemistry, to The Dow Chemical Company, United States, was signed in December 2006. Wolff Walsrode also was formerly assigned to the Materials segment. Pending the approval of the antitrust authorities, the transfer of this business is expected to take place in the summer of 2007.

The Diagnostics activities, H.C. Starck and Wolff Walsrode are recognized as discontinued operations. The prior-period data have been restated accordingly.

This information, which is provided from the standpoint of the Bayer Group, is to be regarded as part of the reporting for the entire Bayer Group by analogy with our segment reporting and is not intended to portray either the discontinued operations or the remaining operations of Bayer as separate entities. This presentation is thus in line with the principles for reporting discontinued operations.

Discontinued Operations

	Diagnostics		H.C. Starck		Wolff Walsrode			Total
	1st	1st	1st	1st	1st	1st	1st	1st
million	Quarter	Quarter	Quarter	Quarter	Quarter	Quarter	Quarter	Quarter
	2006	2007	2006	2007	2006	2007	2006	2007
Net sales	378	0	247	74	78	85	703	159
Operating result (EBIT)*	31	2,778	22	109	6	13	59	2,900
Income after taxes	21	2,044	12	103	2	7	35	2,154
Gross cash flow*	64	(10)	27	14	10	10	101	14
Net cash flow*	64	7	26	26	0	5	90	38
Net investing cash flow	(29)	3,748	(10)	922	(2)	(2)	(41)	4,668
Net financing cash flow	(35)	(3,755)	(16)	(948)	2	(3)	(49)	(4,706)

* for definition
see Bayer
Group Key Data
on page 2

Related parties

In the course of the operating business, materials, inventories and services are sourced from a large number of business partners around the world. These include companies in which an interest is held, and companies with which members of the Supervisory Board of Bayer AG are associated. Transactions with these companies are carried out on an arm's-length basis. Business with such companies was not material from the viewpoint of the Bayer Group. The Bayer Group was not a party to any transaction of an unusual nature or structure that was material to it or to companies or persons closely associated with it, nor does it intend to be party to such transactions in the future.

Table of Contents

Interim Report as of March 31, 2007

Business transactions with companies included in the consolidated financial statements at equity, or at cost less impairment charges, mainly comprised trade in goods and services. The value of these transactions was, however, immaterial from the point of view of the Bayer Group. The same applies to financial receivables and payables vis-à-vis related parties.

Other information

The Annual Stockholders Meeting on April 27, 2007 approved the dividend proposed by the Board of Management and Supervisory Board of 1.00 per share for fiscal 2006.

The stockholders also ratified the actions of the members of the Board of Management and the Supervisory Board. The terms of office of all Supervisory Board members ended at the close of the 2007 Annual Stockholders Meeting. In addition to the previous Supervisory Board members Dr. Paul Achleitner, Prof. Dr.-Ing. h.c. Hans-Olaf Henkel, Dr. Klaus Kleinfeld, Dr. Manfred Schneider, Dr. Ekkehard D. Schulz, Dr.-Ing. h.c. Jürgen Weber and Prof. Dr. Dr. h.c. Ernst-Ludwig Winnacker, the Annual Stockholders Meeting elected Dr. Clemens Börsig, Chairman of the Supervisory Board of Deutsche Bank Aktiengesellschaft, Dr. Helmut Panke, former Chairman of the Board of Management of BMW Aktiengesellschaft, and Dr. Klaus Sturany, member of the Board of Management of RWE Aktiengesellschaft, as stockholders representatives on the Supervisory Board. They will hold office until the conclusion of the Annual Stockholders Meeting that resolves on the ratification of the actions of the members of the Supervisory Board for the 2011 fiscal year. In addition to the previous Supervisory Board members Willy Beumann, Karl-Josef Ellrich, Dr.-Ing. Thomas Fischer, Peter Hausmann, Rainer Hoffmann, Petra Kronen, Hubertus Schmoldt and Thomas de Win, the employee delegates assembly elected Oliver Zühlke and André Krejcik as employees representatives on the Supervisory Board.

The existing Authorized Capital ii was revoked and new Authorized Capital ii created with the option of excluding subscription rights; Section 4, Paragraph 3 of the Articles of Incorporation (Capital Stock) was amended accordingly. Due to the expiration of the authorization given by the previous Annual Stockholders Meeting, the Board of Management was again authorized to purchase and sell company shares subject to exclusion of subscription rights. The Annual Stockholders Meeting approved the Control Agreement between Bayer AG and Bayer Schering GmbH. PricewaterhouseCoopers Aktiengesellschaft, Wirtschaftsprüfungsgesellschaft, Essen, Germany, was appointed as auditor for the 2007 fiscal year as well as for the audit review of the semi-annual financial report for the 2007 fiscal year.

Leverkusen, May 2, 2007
Bayer Aktiengesellschaft
The Board of Management

Table of Contents

Masthead

Published by

Bayer AG, 51368 Leverkusen, Germany

Editor

Ute Bode, phone ++49 214 30 58992, email: ute.bode.ub@bayer-ag.de

English edition

Bayer Industry Services GmbH & Co. OHG, Central Language Service

Investor Relations

Peter Dahlhoff, phone ++49 214 30 33022, email: peter.dahlhoff@bayer-ag.de

Orders/Distribution

Michael Heinrich, phone ++49 214 30 57546, email: serviceline@bayer-ag.de

Date of publication

May 8, 2007

Many business and financial terms are explained on the Bayer Investor Relations website at www.investor.bayer.com>Stock>Glossary

Bayer on the Internet

www.bayer.com

If you would like to receive the Bayer Stockholders Newsletter in electronic rather than print form in future, please email the editor.

Forward-Looking Statements

This Annual Report contains forward-looking statements. These statements use words like believes, assumes, expects or similar formulations. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, assets, development or performance of our company and those either expressed or implied by these statements. These factors include, among other things:

- downturns in the business cycle of the industries in which we compete;

- new regulations, or changes to existing regulations, that increase our operating costs or otherwise reduce our profitability;

- increases in the price of our raw materials, especially if we are unable to pass these costs along to customers;

- loss or reduction of patent protection for our products;

- liabilities, especially those incurred as a result of environmental laws or product liability litigation;

- fluctuation in international currency exchange rates as well as changes in the general economic climate; and

- other factors identified in this Annual Report.

These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). In view of these uncertainties, we caution readers not to place undue reliance on these forward-looking statements. We assume no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Important Information from Bayer AG:

This is neither an offer to purchase nor a solicitation of an offer to sell shares or American depositary shares of Bayer Schering Pharma AG (formerly Schering AG). Bayer Schering GmbH (formerly Dritte BV GmbH) filed a tender offer statement with the U.S. Securities and Exchange Commission (SEC) with respect to the mandatory compensation offer on November 30, 2006, the time of commencement of the mandatory compensation offer. Simultaneously Bayer Schering Pharma AG (formerly Schering AG) filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the mandatory compensation offer. Investors and holders of shares and American depositary

shares of Bayer Schering Pharma AG (formerly Schering AG) are strongly advised to read the tender offer statement and other relevant documents regarding the mandatory compensation offer that have been filed or will be filed with the SEC because they contain important information. Investors and holders of shares and American depositary shares of Bayer Schering Pharma AG (formerly Schering AG) will be able to receive these documents free of charge at the SEC's website (www.sec.gov), or at the website www.bayer.com.

These documents and information contain forward-looking statements based on assumptions and forecasts made by Bayer Group management as of the respective dates of such documents. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Bayer Group and/or Bayer Schering Pharma AG (formerly Schering AG) and the estimates contained in these documents and to differences between actions taken by the Bayer Group with respect to its investment in Bayer Schering Pharma AG (formerly Schering AG) and the intentions described in these documents. These factors include those discussed in reports filed with the Frankfurt Stock Exchange and in our reports filed with the U.S. Securities and Exchange Commission (including on Form 20-F). All forward-looking statements in these documents are made as of the dates thereof, based on information available to us as of the dates thereof. Except as otherwise required by law, we assume no obligation to update or revise any forward-looking statement to reflect new information, events or circumstances after the applicable dates thereof.

The names Bayer Schering Pharma or Schering as used in this publication always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively.

Please note that Bayer Schering Pharma AG is not legally related to Schering-Plough Corporation, New Jersey, United States. The two companies have been totally independent of each other for many years.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BAYER AKTIENGESELLSCHAFT
(Registrant)

By: /s/ Dr. Roland Hartwig
Name: Dr. Roland Hartwig
Title: General Counsel

By: /s/ ppa. D_{R.} A_{RMIN} B_{UCHMEIER}
Name: Dr. Armin Buchmeier
Title: Senior Counsel

Date: May 10, 2007